Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 108,011 shares of Cerus stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.59, for a total transaction of $387,759.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Cerus stock traded up $0.32 during trading on Thursday, hitting $4.36. The stock had a trading volume of 65,891 shares, compared to its average volume of 2,274,683. The stock has a 50 day simple moving average of $4.66 and a 200 day simple moving average of $4.51. The company has a market capitalization of $624.34 million, a PE ratio of -8.31 and a beta of 1.19. The company has a quick ratio of 2.16, a current ratio of 2.55 and a debt-to-equity ratio of 1.01. Cerus Co. has a 1 year low of $2.71 and a 1 year high of $6.64.
Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01). Cerus had a negative net margin of 95.44% and a negative return on equity of 112.64%. The firm had revenue of $20.92 million during the quarter, compared to analysts’ expectations of $20.90 million. As a group, equities analysts expect that Cerus Co. will post -0.44 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Cerus from a “sell” rating to a “hold” rating in a research note on Wednesday, March 18th. BidaskClub lowered Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. BTIG Research assumed coverage on Cerus in a report on Wednesday, February 26th. They set a “buy” rating and a $7.00 target price for the company. Finally, ValuEngine upgraded Cerus from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $7.33.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also: Gross Domestic Product (GDP)
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.